BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 7687071)

  • 1. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.
    Zaltzman AB; Van den Berg CW; Muzykantov VR; Morgan BP
    Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):651-6. PubMed ID: 7537958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.
    Miyagawa S; Mikata S; Shirakura R; Matsuda H; Nagasawa S; Terados A; Hatanaka M; Matsumoto M; Seya T
    Scand J Immunol; 1996 Apr; 43(4):361-6. PubMed ID: 8668913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibility of prevention of hyperacute rejection by DAF and CD59 in xenotransplantation.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Seya T
    Transplant Proc; 1994 Jun; 26(3):1235-8. PubMed ID: 7518114
    [No Abstract]   [Full Text] [Related]  

  • 8. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted.
    van den Berg CW; Morgan BP
    J Immunol; 1994 Apr; 152(8):4095-101. PubMed ID: 7511666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA).
    Arora M; Kumar A; Das SN; Srivastava LM
    Clin Exp Immunol; 1998 Jan; 111(1):102-6. PubMed ID: 9472668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Hatanaka M; Inai S; Matsumoto M; Miyagawa S; Masaoka T; Kanamaru A; Kawakita M; Yonemura Y; Sugita Y; Seya T
    Clin Immunol Immunopathol; 1993 Oct; 69(1):52-9. PubMed ID: 7691453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion.
    McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL
    Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation between human DAF and CD59 in protecting cells from human complement-mediated lysis.
    Xu L; Wu W; Zhao Z; Shao H; Liu W; Liu H; Li W
    J Biochem Mol Biol; 2006 Nov; 39(6):743-8. PubMed ID: 17129411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classical pathway complement destruction is not responsible for the loss of human erythrocytes during porcine liver perfusion.
    Rees MA; Butler AJ; Negus MC; Davies HF; Friend PJ
    Transplantation; 2004 May; 77(9):1416-23. PubMed ID: 15167601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.